Home / Business and Economy / Pharma Giants Face Lawsuit Over Weight-Loss Drug Access
Pharma Giants Face Lawsuit Over Weight-Loss Drug Access
16 Jan
Summary
- Compounding pharmacy sued Eli Lilly and Novo Nordisk in Texas.
- Allegations include blocking access to customized weight-loss drugs.
- Lawsuit seeks damages and an order to end exclusivity agreements.
Eli Lilly and Novo Nordisk are facing a lawsuit filed by compounding pharmacy Strive Specialties in San Antonio, Texas. The pharmacy alleges that the drugmakers have illegally obstructed access to personalized versions of their blockbuster GLP-1 drugs, which are in high demand for diabetes and weight loss. Strive contends that exclusivity deals with major telehealth providers prevent doctors from prescribing compounded GLP-1 medications, even when a patient requires a tailored formulation.
Strive Specialties claims that Eli Lilly has also disparaged compounded drugs as unsafe and interfered with the pharmacy's business relationships. The compounding sector argues it fills a crucial gap, especially during drug shortages, by providing options not offered by branded products. The lawsuit, filed on Wednesday, seeks substantial monetary damages and a court injunction against the alleged exclusivity agreements.
Both Eli Lilly and Novo Nordisk have issued statements vehemently denying the allegations. Eli Lilly stated the lawsuit is factually and legally incorrect, an attempt to deflect from Strive's own conduct. Novo Nordisk asserted the claims are baseless and vowed vigorous legal defense. This legal battle highlights the ongoing tension between major pharmaceutical companies and compounding pharmacies over access and pricing of high-demand GLP-1 medications.
